

UNIVERSITY OF THE YEAR

Decision Curve Analysis

Dr. Fani Deligianni,

fani.deligianni@glasgow.ac.uk

Lecturer (Assistant Professor)

nttps://www.gla.ac.uk/schools/computing/staff/fanideligianni Lead of the Computing Technologies for Healthcare Theme



Clinical Consequences

- Breast cancer detection as a use case:
- A false-negative result is much more harmful than a false-positive
- A model with greater specificity but slightly worse sensitivity could have a better AUC
- Worse choice for a clinical decision system for breast cancer detection



Decision Analysis

- **Decision Trees**
- Assign probabilities and
- Explicit valuation of health outcomes
- Number of complications prevented
 - Quality-adjusted life-years saved



A Simpler Method

For each model:

For p_t in range(a,b):

• Calculate the number of true- and false-positive results using p_t as the cut-point for determining a positive or negative result.

$$Net \, Benefit = rac{True \, Positives}{N} - rac{False \, Positives}{N} \, x \, rac{p_t}{1 - p_t}$$

A Simpler Method

For each model:

For p_t in range(a,b):

Calculate the number of true- and false-positive results using p_t as the cut-point for determining a positive or negative result.

Net Benefit =
$$\frac{True\ Positives}{N} - \frac{False\ Positives}{N} \times \frac{p_t}{1-p_t}$$

- Plot net benefit on the y axis against p_t on the x axis.
- Repeat steps assuming all patients are positive
- Draw a straight line parallel to the x-axis at y=0 representing the net benefit associated with the strategy of assuming that all patients are negative






Decision Curve Analysis - Examples

- Prostate cancer with elevated PSA intervention would mean a biopsy
- In patients with an infection intervention would mean antibiotics
- In preventing heart disease intervention might be statins/medication
- Decision curve analysis includes results for
- 'intervention for all'
- 'intervention for none'

$$Net\ Benefit = rac{True\ Positives}{N} - rac{False\ Positives}{N} rac{p_t}{1-p_t}$$

Decision Curve Analysis


- Compare model with treating all positive, treating none or treating based on the duration of untreated psychosis alone
- Treatment probability threshold: 40-60%



Leighton et al. 2021

Theoretical Examples

- Disease incidence is 20%
- Sensitivity vs Specificity across threshold probabilities



= sensitivity x prevalence -(1-specificity)x(1-prevalance) x $\frac{1}{1-Threshold\ Probability}$ Threshold Probabilty


Net Benefit

Vickers et al. 'Decision curve analysis: a novel method for evaluating prediction models', 2006



Theoretical Examples

- Disease incidence is 20%
- Laboratory test, normally distributed



Net Benefit

= sensitivity x prevalence -(1-specificity)x(1-prevalance)x $\frac{1-Threshold\ Probability}{1-Threshold\ Probability}$ Threshold Probabilty

Vickers et al. 'Decision curve analysis: a novel method for evaluating prediction models', 2006



Summary

- Incorporating clinical consequences is important in clinical decision models
- Clinical benefits can be easily quantified with decision curve analysis
- Decision curve analysis is an intuitive way to compare prediction models
- Decision curves do not replace other forms of validation and measures of accuracy

References

- Vickers et al. 'Decision curve analysis: a novel method for evaluating prediction models', Med. Decis. Making, 2006.
- Calster et al. 'Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators', European Urology, 2018.
- Vicker et al. 'A simple, step-by-step guide to interpreting decision curve analysis', Diagnostic and Prognostic Research, 2019.
- Capogrosso et al. 'A Systematic Review of the Literature Demonstrates Some Errors in the Use of Decision Curve Analysis but Generally Correct Interpretation of Findings', 2019.
- recovery, and quality of life outcomes in people with first episode psychosis: a machine learning Leighton et al. Development and validation of multivariable prediction models of remission, approach, The Lancet: Digital Health, 2019.
- Leighton et al. Development and validation of a non-remission risk prediction model in First Episode Psychosis: An analysis of two longitudinal studies, BJPsych Open, 2021.